Canada markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.35+0.07 (+1.11%)
As of 10:01AM EDT. Market open.
Currency in USD

Valuation Measures4

Market Cap (intraday) 1.30B
Enterprise Value 1.79B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)3.47
Price/Book (mrq)56.59
Enterprise Value/Revenue 5.03
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 1.96
52-Week Change 3-26.72%
S&P500 52-Week Change 326.49%
52 Week High 38.96
52 Week Low 34.03
50-Day Moving Average 34.95
200-Day Moving Average 35.85

Share Statistics

Avg Vol (3 month) 33.56M
Avg Vol (10 day) 35.18M
Shares Outstanding 5206.38M
Implied Shares Outstanding 6206.38M
Float 8191.28M
% Held by Insiders 11.12%
% Held by Institutions 189.98%
Shares Short (Apr 30, 2024) 433.64M
Short Ratio (Apr 30, 2024) 410.67
Short % of Float (Apr 30, 2024) 416.43%
Short % of Shares Outstanding (Apr 30, 2024) 416.30%
Shares Short (prior month Mar 28, 2024) 432.25M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin -58.69%
Operating Margin (ttm)-15.62%

Management Effectiveness

Return on Assets (ttm)-10.85%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)355.4M
Revenue Per Share (ttm)1.81
Quarterly Revenue Growth (yoy)34.90%
Gross Profit (ttm)N/A
EBITDA -82.09M
Net Income Avi to Common (ttm)-208.58M
Diluted EPS (ttm)-1.07
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)336.55M
Total Cash Per Share (mrq)1.63
Total Debt (mrq)852.9M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.73
Book Value Per Share (mrq)-2.31

Cash Flow Statement

Operating Cash Flow (ttm)-101.31M
Levered Free Cash Flow (ttm)-72.42M